About this Research Topic
Cancer is defined as a malignant proliferation of cells influenced by several genetic and environmental factors. Cancer is still a major cause of morbidity and mortality globally. The increase in cancer incidence because of prolonged life expectancy together with a rise in world population and risk factors, is still increasing. Fighting against cancer through the improvement of diagnosis and treatment approaches therefore requires to keep exploring cellular and molecular processes supporting the disease.
Among the processes causally associated to cancer progression are hypoxia and angiogenesis. Indeed, these two factors have been documented to lead to cancer cell survival, resistance to therapy, local invasiveness, and metastasis. In particular, hypoxia-inducible factors (HIFs), vascular endothelial growth factors (VEGFs), and their receptors (VEGFRs) have been shown to be crucial mediators in cancer progression alongside prominent signaling pathways, including MAPK/ERK, PKC, PLC-γ, FAK, p38, and PI3K. This Research Topic aims to provide an opportunity to collect articles investigating different aspects of the significance of hypoxia and angiogenesis in cancer and drug development. We welcome Original Research, Reviews, and Mini-Reviews, focusing on the following areas:
• Hypoxia and related signaling pathways in cancer
• Angiogenesis and related signaling pathways in cancer
• Interplay between hypoxia and angiogenesis in cancer
• Prognostic significance of hypoxia, angiogeneis and associated pathways in cancer
• Diagnostic insights related to hypoxia and angiogenesis in early steps of tumorigenesis
• Targeting hypoxia in cancer treatment
• Targeting angiogenesis in cancer treatment
Among the processes causally associated to cancer progression are hypoxia and angiogenesis. Indeed, these two factors have been documented to lead to cancer cell survival, resistance to therapy, local invasiveness, and metastasis. In particular, hypoxia-inducible factors (HIFs), vascular endothelial growth factors (VEGFs), and their receptors (VEGFRs) have been shown to be crucial mediators in cancer progression alongside prominent signaling pathways, including MAPK/ERK, PKC, PLC-γ, FAK, p38, and PI3K. This Research Topic aims to provide an opportunity to collect articles investigating different aspects of the significance of hypoxia and angiogenesis in cancer and drug development. We welcome Original Research, Reviews, and Mini-Reviews, focusing on the following areas:
• Hypoxia and related signaling pathways in cancer
• Angiogenesis and related signaling pathways in cancer
• Interplay between hypoxia and angiogenesis in cancer
• Prognostic significance of hypoxia, angiogeneis and associated pathways in cancer
• Diagnostic insights related to hypoxia and angiogenesis in early steps of tumorigenesis
• Targeting hypoxia in cancer treatment
• Targeting angiogenesis in cancer treatment
Keywords: Angiogenesis, Hypoxia, Cancer, Hypoxia-Inducible Factors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor Receptor
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
